CAR-T found to be safe and effective on an outpatient basis in community hospitals

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded well to treatment with few serious side effects, according to results published in Blood Advances.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup